Biopharmaceutical company Covistat said on Thursday that it is one step closer in developing the low cost treatment nafamostat for COVID-19 via the acquisition of the technology and intellectual property of Mucokinetica.
In the fight against COVID-19, Dr Peter Cole and Dr Rod Hall, founders of Mucokinetica Ltd and world-leading experts in respiratory diseases and cystic fibrosis, are joining the Covistat team. Mucokinetica's technology and intellectual property will accelerate the efforts to develop a low-cost treatment that helps the body's ability to block the coronavirus and its mutating variations from infiltrating our cells.
The companies added that nafamostat blocks TMPRSS2, the enzyme that enables SARS-CoV-2's spike proteins to gain entry into cells. Whether suffering from mild symptoms at home or acute respiratory failure in a hospital, nafamostat's therapy is expected to reduce the viral load in patients and prevent the progression of COVID-19.
Additionally, Covistat is working to repurpose this proven generic drug nafamostat into oral, intranasal and inhaled therapies for COVID-19 patients, including those in remote and developing regions of the world.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients